Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Liraglutide
60
CHF
CHF 60.00
In stock
AG-CP3-0034-M0011 mgCHF 60.00
AG-CP3-0034-M0055 mgCHF 160.00
AG-CP3-0034-M02525 mgCHF 450.00
AG-CP3-0034-M100100 mgCHF 1'100.00
BULK available!
Research Use Only (RUO). NOT ALLOWED FOR USE IN HUMANS.
![Loading...](https://adipogen.com/pub/static/version1703841973/frontend/raffiniert/adipogen/de_CH/images/loader-1.gif)
Product Details | |
---|---|
Synonyms | Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37); NN2211; NNC 90-1170; Victoza |
Product Type | Chemical |
Properties | |
Formula |
C172H265N43O51 |
MW | 3751.2 |
Sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
CAS | 204656-20-2 |
Source/Host Chemicals | Synthetic. |
Purity Chemicals | ≥98% (HPLC) |
Appearance | White to off-white powder. |
Solubility | Freely soluble in aqueous base (>pH7). Soluble in methanol (20mg/ml) and slightly soluble in DMSO or ethanol (1mg/ml). |
InChi Key | YSDQQAXHVYUZIW-QCIJIYAXSA-N |
Smiles | O=C([C@H](CC(C)C)N([H])C([C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C([C@H](C)N([H])C([C@H]([C@@H](C)CC)N([H])C([C@H](CC3=CC=CC=C3)N([H])C([C@H](CCC(O)=O)N([H])C([C@H](CCCCN([H])C(CC[C@@H](C(O)=O)N([H])C(CCCCCCCCCCCCCCC)=O)=O)N([H])C([C@H](C)N([H])C([C@H](C)N([H])C([C@H](CCC(N([H])[H])=O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](CC(C)C)N([H])C([C@H](CC(C=C4)=CC=C4O)N([H])C([C@H](CO)N([H])C([C@H](CO)N([H])C([C@H](C(C)C)N([H])C([C@H](CC(O)=O)N([H])C([C@H](CO)N([H])C([C@H]([C@@H](C)O)N([H])C([C@H](CC5=CC=CC=C5)N([H])C([C@H]([C@@H](C)O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](C)N([H])C([C@H](CC6=CN=CN6[H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N([H])[C@H](C(N([H])[C@H](C(N([H])CC(N([H])[C@H](C(N([H])CC(O)=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)C(C)C |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Keep cool and dry. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
Description
- Long-acting acylated glucagon-like peptide-1 (GLP-1) receptor agonist.
- Antidiabetic and antiobesity agent used clinically to treat type 2 diabetes mellitus. Binding to GLP-1R, activates AMP-activated protein kinase, consequently stimulates insulin secretion in pancreatic β cells and suppresses glucagon secretion in a glucose-dependent manner. Improves control of blood glucose and consequently modulates appetite and body weight.
- Inhibits β cell apoptosis and improves β cell mass.
- Shown to ameliorate glycometabolism and insulin resistance through the upregulation of GLUT4.
- Neuroprotective. Prevents neurodegenerative processes in pathologies such as Alzheimer's and Parkinson's disease.
- Anti-inflammatory agent. Exerts cardioprotective roles via activating prosurvival pathways and suppressing inflammation. Anti-pyroptotic by inhibiting TNF-α and hypoxia-induced inflammasome activation.
- Anticancer agent. Inhibited proliferation and induced apoptosis in cancer cell lines.
- Shown to inhibit osteoclastogenesis.
Product References
- The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men: H. Agerso, et al.; Diabetologia 45, 195 (2002)
- The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice: B. Rolin, et al.; Am. J. Physiol. Endocrinol. Metab. 283, E745 (2002)
- The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro: S. Bregenholt, et al.; BBRC 330, 577 (2005)
- Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog: J. Meece; Pharmacotherapy 29, 33S (2009) (Review)
- The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease: P.L. McClean, et al.; J. Neurosci. 31, 6587 (2011)
- Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection: C. Hoelscher; CNS Drugs 26, 871 (2012) (Review)
- Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice: L.N. Chen, et al.; Int. J. Mol. Med. 32, 892 (2013)
- Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease: P.L. McClean & C. Hoelscher; Neuropharmacol. 76, 57 (2014)
- Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism: N.M. Krasner, et al.; PLoS One 9, e97554 (2014)
- Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes: M. Garg, et al.; Diabetes Obes. Metab. 19, 1306 (2017)
- Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells: G.C. Krause, et al.; Eur. J. Pharmacol. 809, 32 (2017)
- Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression: W. Zhao, et al.; Mol. Med. Rep. 17, 5202 (2018)
- Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells: A. Chen, et al.; BBRC 499, 267 (2018)
- Liraglutide Modulates Appetite and Body Weight Via GLP-1R-Expressing Glutamatergic Neurons: J.M. Adams, et al.; Diabetes 67, 1538 (2018)
- Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis: B. Wen, et al.; Exp. Ther. Med. 15, 5077 (2018)
- Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes: B. Yesildag, et al.; Clin. Immunol. 244, 109118 (2022)
- Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats: S.B. Reddiar, et al.; Eur. J. Pharm. Biopharm. 200, 114339 (2024)